Literature DB >> 18068872

Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS.

Ilse Gijselinck1, Kristel Sleegers, Sebastiaan Engelborghs, Wim Robberecht, Jean-Jacques Martin, Rik Vandenberghe, Raf Sciot, Bart Dermaut, Dirk Goossens, Julie van der Zee, Tim De Pooter, Jurgen Del-Favero, Patrick Santens, Peter De Jonghe, Peter P De Deyn, Christine Van Broeckhoven, Marc Cruts.   

Abstract

The nuclear TAR DNA binding protein (TDP-43) is deposited in ubiquitin-positive inclusions in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), two clinicopathologically overlapping neurodegenerative diseases. In this study we excluded mutations and copy number variations in the gene encoding TDP-43 (TARDBP) from an extended series of 173 FTD and 237 ALS patients. Further, we did not identify association of common genetic variants in these patients. Our data implicate that TDP-43 has no primary genetic role in the pathophysiological mechanisms underlying central nervous system neurodegeneration in these diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18068872     DOI: 10.1016/j.neurobiolaging.2007.11.002

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  30 in total

Review 1.  Update on recent molecular and genetic advances in frontotemporal lobar degeneration.

Authors:  Eileen H Bigio
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

Review 2.  Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration.

Authors:  T F Gendron; K A Josephs; L Petrucelli
Journal:  Neuropathol Appl Neurobiol       Date:  2010-02-19       Impact factor: 8.090

Review 3.  Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management.

Authors:  Gil D Rabinovici; Bruce L Miller
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

Review 4.  The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Ian R A Mackenzie; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

Review 5.  Targeting angiogenin in therapy of amyotropic lateral sclerosis.

Authors:  Hiroko Kishikawa; David Wu; Guo-fu Hu
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

Review 6.  Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases.

Authors:  Felix Geser; Maria Martinez-Lage; Linda K Kwong; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Neurol       Date:  2009-03-07       Impact factor: 4.849

7.  Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis.

Authors:  Janine Kirby; Emily F Goodall; William Smith; J Robin Highley; Rudo Masanzu; Judith A Hartley; Rachel Hibberd; Hannah C Hollinger; Stephen B Wharton; Karen E Morrison; Paul G Ince; Christopher J McDermott; Pamela J Shaw
Journal:  Neurogenetics       Date:  2009-09-17       Impact factor: 2.660

8.  Association between novel TARDBP mutations and Chinese patients with amyotrophic lateral sclerosis.

Authors:  Hui-Ling Xiong; Jin-Yang Wang; Yi-Min Sun; Jian-Jun Wu; Yan Chen; Kai Qiao; Qiao-Juan Zheng; Gui-Xian Zhao; Zhi-Ying Wu
Journal:  BMC Med Genet       Date:  2010-01-19       Impact factor: 2.103

9.  Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS).

Authors:  Laura E Cox; Laura Ferraiuolo; Emily F Goodall; Paul R Heath; Adrian Higginbottom; Heather Mortiboys; Hannah C Hollinger; Judith A Hartley; Alice Brockington; Christine E Burness; Karen E Morrison; Stephen B Wharton; Andrew J Grierson; Paul G Ince; Janine Kirby; Pamela J Shaw
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

Review 10.  Molecular neuropathology of TDP-43 proteinopathies.

Authors:  Manuela Neumann
Journal:  Int J Mol Sci       Date:  2009-01-09       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.